Literature DB >> 29691481

Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis.

Sabine Ehrt1, Dirk Schnappinger2, Kyu Y Rhee3.   

Abstract

Metabolism was once relegated to the supply of energy and biosynthetic precursors, but it has now become clear that it is a specific mediator of nearly all physiological processes. In the context of microbial pathogenesis, metabolism has expanded outside its canonical role in bacterial replication. Among human pathogens, this expansion has emerged perhaps nowhere more visibly than for Mycobacterium tuberculosis, the causative agent of tuberculosis. Unlike most pathogens, M. tuberculosis has evolved within humans, which are both host and reservoir. This makes unrestrained replication and perpetual quiescence equally incompatible strategies for survival as a species. In this Review, we summarize recent work that illustrates the diversity of metabolic functions that not only enable M. tuberculosis to establish and maintain a state of chronic infection within the host but also facilitate its survival in the face of drug pressure and, ultimately, completion of its life cycle.

Entities:  

Mesh:

Year:  2018        PMID: 29691481      PMCID: PMC6045436          DOI: 10.1038/s41579-018-0013-4

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  121 in total

1.  Methylcitrate cycle defines the bactericidal essentiality of isocitrate lyase for survival of Mycobacterium tuberculosis on fatty acids.

Authors:  Hyungjin Eoh; Kyu Y Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

2.  Fumarase Deficiency Causes Protein and Metabolite Succination and Intoxicates Mycobacterium tuberculosis.

Authors:  Nadine Ruecker; Robert Jansen; Carolina Trujillo; Susan Puckett; Pradeepa Jayachandran; Gerardo G Piroli; Norma Frizzell; Henrik Molina; Kyu Y Rhee; Sabine Ehrt
Journal:  Cell Chem Biol       Date:  2017-02-16       Impact factor: 8.116

3.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

4.  Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds.

Authors:  J BERNSTEIN; W A LOTT; B A STEINBERG; H L YALE
Journal:  Am Rev Tuberc       Date:  1952-04

Review 5.  Mycobacterial genes essential for the pathogen's survival in the host.

Authors:  Sabine Ehrt; Kyu Rhee; Dirk Schnappinger
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

Review 6.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

Review 7.  Recent advances in deciphering the contribution of Mycobacterium tuberculosis lipids to pathogenesis.

Authors:  Olivier Neyrolles; Christophe Guilhot
Journal:  Tuberculosis (Edinb)       Date:  2011-02-16       Impact factor: 3.131

8.  Genetic requirements for mycobacterial survival during infection.

Authors:  Christopher M Sassetti; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

9.  Metabolic regulation of mycobacterial growth and antibiotic sensitivity.

Authors:  Seung-Hun Baek; Alice H Li; Christopher M Sassetti
Journal:  PLoS Biol       Date:  2011-05-24       Impact factor: 8.029

10.  The Cell Wall Lipid PDIM Contributes to Phagosomal Escape and Host Cell Exit of Mycobacterium tuberculosis.

Authors:  Jeff Quigley; V Keith Hughitt; Carlos A Velikovsky; Roy A Mariuzza; Najib M El-Sayed; Volker Briken
Journal:  mBio       Date:  2017-03-07       Impact factor: 7.867

View more
  51 in total

Review 1.  Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.

Authors:  Claire Healy; Natalia Munoz-Wolf; Janné Strydom; Lynne Faherty; Niamh C Williams; Sarah Kenny; Seamas C Donnelly; Suzanne M Cloonan
Journal:  Respir Res       Date:  2021-04-29

Review 2.  The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  J Mol Biol       Date:  2019-02-21       Impact factor: 5.469

3.  Zebrafish Embryo Model for Assessment of Drug Efficacy on Mycobacterial Persisters.

Authors:  Susanna Commandeur; Nino Iakobachvili; Marion Sparrius; Mariam Mohamed Nur; Galina V Mukamolova; Wilbert Bitter
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization.

Authors:  Mark R Cronan; Erika J Hughes; W Jared Brewer; Gopinath Viswanathan; Emily G Hunt; Bindu Singh; Smriti Mehra; Stefan H Oehlers; Simon G Gregory; Deepak Kaushal; David M Tobin
Journal:  Cell       Date:  2021-03-23       Impact factor: 41.582

5.  Mycobacterial fatty acid catabolism is repressed by FdmR to sustain lipogenesis and virulence.

Authors:  Wenyue Dong; Xiaoqun Nie; Hong Zhu; Qingyun Liu; Kunxiong Shi; Linlin You; Yu Zhang; Hongyan Fan; Bo Yan; Chen Niu; Liang-Dong Lyu; Guo-Ping Zhao; Chen Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

Review 6.  Ribosome hibernation: a new molecular framework for targeting nonreplicating persisters of mycobacteria.

Authors:  Yunlong Li; Manjuli R Sharma; Ravi K Koripella; Nilesh K Banavali; Rajendra K Agrawal; Anil K Ojha
Journal:  Microbiology (Reading)       Date:  2021-02       Impact factor: 2.777

Review 7.  The knowns and unknowns of latent Mycobacterium tuberculosis infection.

Authors:  W Henry Boom; Ulrich E Schaible; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

8.  Metabolic bifunctionality of Rv0812 couples folate and peptidoglycan biosynthesis in Mycobacterium tuberculosis.

Authors:  Katherine A Black; Lijun Duan; Lungelo Mandyoli; Bruna P Selbach; Weizhen Xu; Sabine Ehrt; James C Sacchettini; Kyu Y Rhee
Journal:  J Exp Med       Date:  2021-05-05       Impact factor: 17.579

9.  Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.

Authors:  Sarah Kim; Walter M Yamada; Brandon Duncanson; Jocelyn Nole; Stephanie Rogers; Sarah Parker; Meredith Bacci; Nino Mtchedlidze; Charles A Peloquin; Arnold Louie; Stephan Schmidt; George L Drusano; Michael N Neely
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

Review 10.  Platelet Activation and the Immune Response to Tuberculosis.

Authors:  Daniela E Kirwan; Deborah L W Chong; Jon S Friedland
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.